Incyte's Tafasitamab Trial Achieves Key Milestones for DLBCL Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 05 2026
0mins
Source: Benzinga
- Trial Result Breakthrough: Incyte's tafasitamab, in combination with lenalidomide, successfully met its primary endpoint of progression-free survival (PFS) in the pivotal frontMIND Phase 3 trial, indicating significant potential efficacy for newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients.
- Safety Assessment: No new safety signals were observed during the trial, which enhances confidence in tafasitamab as a first-line treatment option and may promote its acceptance and usage in the market.
- Market Application Plans: Incyte expects to file a supplemental Biologics License Application (sBLA) for tafasitamab as a first-line treatment for newly diagnosed DLBCL patients in the first half of 2026, demonstrating the company's commitment to the drug's future market potential.
- Market Competition Analysis: Despite the positive trial results, analyst William Blair notes that the indication expansion opportunity for Monjuvi in frontline DLBCL may be limited due to the presence of several competing novel R-CHOP-based regimens currently in Phase 3 trials.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INCY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INCY
Wall Street analysts forecast INCY stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for INCY is 100.31 USD with a low forecast of 73.00 USD and a high forecast of 125.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
9 Buy
9 Hold
1 Sell
Moderate Buy
Current: 101.180
Low
73.00
Averages
100.31
High
125.00
Current: 101.180
Low
73.00
Averages
100.31
High
125.00
About INCY
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analysts Downgrade Incyte Target to $107 Amid Market Adjustments
- Incyte Price Target Cut: Wells Fargo downgraded Incyte's price target from $116 to $107 and changed its rating from Overweight to Equal-Weight, reflecting a cautious market sentiment as shares closed at $106.21 on Friday.
- Uber Target Adjustment: Keybanc reduced Uber's price target from $110 to $105 while maintaining an Overweight rating, indicating analysts' confidence in Uber's future growth, with shares closing at $84.85 on Friday.
- Philip Morris Downgrade: Jefferies cut Philip Morris's price target from $220 to $180 and downgraded its rating from Buy to Hold, reflecting concerns about the company's future performance as shares closed at $173.62 on Friday.
- Prologis Price Target Increase: Truist Securities raised Prologis's price target from $131 to $142 while maintaining a Buy rating, indicating analysts' optimism about its future growth, with shares closing at $133.21 on Friday.
Continue Reading
BofA Identifies 20 Most Favored Stocks by Hedge Funds
- Hedge Fund Favorites: BofA has identified 20 stocks favored by hedge funds, with Incyte Corporation (INCY) leading at a net relative weight of 32.26%, indicating strong appeal in the biotech sector.
- Industry Distribution: The selected stocks span various sectors, including healthcare, technology, and consumer goods, with Centene Corporation (CNC) and Invesco Ltd. (IVZ) following at 19.37% and 17.94%, reflecting hedge funds' emphasis on diversified portfolios.
- Market Trends: Among these favored stocks, VeriSign, Inc. (VRSN) and Mohawk Industries, Inc. (MHK) hold weights of 15.23% and 14.94%, respectively, indicating ongoing market interest in digital security and building materials.
- Investor Confidence: Match Group, Inc. (MTCH) and PG&E Corporation (PCG) are included with weights of 13.52% and 12.63%, showcasing investor confidence in social media and energy sectors, which may influence future market dynamics.
Continue Reading